Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

被引:149
作者
Rodriguez-Novoa, S
Barreiro, P
Rendón, A
Jiménez-Nacher, I
González-Lahoz, J
Soriano, V
机构
[1] Hosp Carlos III, Pharmacokinet Unit, Madrid, Spain
[2] Hosp Carlos III, Infect Dis Serv, Madrid, Spain
关键词
D O I
10.1086/429327
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We examined 516G>T polymorphisms at the gene encoding the cytochrome P450 in 100 human immunodeficiency virus positive subjects who were receiving efavirenz (EFV). Elevated plasma EFV concentrations were found in 40% of subjects with the polymorphic homozygous genotype and 19% of subjects with the heterozygous genotype. Conversely, 20% of subjects with the wild-type genotype had subtherapeutic concentrations of EFV. CYP2B6-516 genotyping may help to identify subjects who have plasma EFV concentrations that are outside of the therapeutic range.
引用
收藏
页码:1358 / 1361
页数:4
相关论文
共 14 条
  • [1] Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz
    Gallego, L
    Barreiro, P
    del Río, R
    de Requena, DG
    Rodríguez-Albariño, A
    González-Lahoz, J
    Soriano, V
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) : 430 - 432
  • [2] HAAS D, 2004, 11 C RETR OPP INF SA, P124
  • [3] Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:: 2003 recommendations of an international AIDS Society-USA panel
    Hirsch, MS
    Brun-Vézinet, F
    Clotet, B
    Conway, B
    Kuritzkes, DR
    D'Aquila, RT
    Demeter, LM
    Hammer, SM
    Johnson, VA
    Loveday, C
    Mellors, JW
    Jacobsen, DM
    Richman, DD
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (01) : 113 - 128
  • [4] Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
    Lang, T
    Klein, K
    Fischer, J
    Nüssler, AK
    Neuhaus, P
    Hofmann, U
    Eichelbaum, M
    Schwab, M
    Zanger, UM
    [J]. PHARMACOGENETICS, 2001, 11 (05): : 399 - 415
  • [5] Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity
    Martin, AM
    Nolan, D
    Gaudieri, S
    Phillips, E
    Mallal, S
    [J]. PHARMACOGENOMICS, 2004, 5 (06) : 643 - 655
  • [6] Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
    Marzolini, C
    Telenti, A
    Decosterd, LA
    Greub, G
    Biollaz, J
    Buclin, T
    [J]. AIDS, 2001, 15 (01) : 71 - 75
  • [7] Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans
    Mouly, S
    Lown, KS
    Kornhauser, D
    Joseph, JL
    Fiske, WD
    Benedek, IH
    Watkins, PB
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (01) : 1 - 9
  • [8] Mutlib AE, 1999, DRUG METAB DISPOS, V27, P1319
  • [9] Gender difference in ifosfamide metabolism by human liver microsomes
    Schmidt, R
    Baumann, F
    Hanschmann, H
    Geissler, F
    Preiss, R
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2001, 26 (03) : 193 - 200
  • [10] Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography
    Tribut, O
    Arvieux, C
    Michelet, C
    Chapplain, JM
    Allain, H
    Bentué-Ferrer, D
    [J]. THERAPEUTIC DRUG MONITORING, 2002, 24 (04) : 554 - 562